Skip to content
MFIC

MidCap Financial Investment Corp

MidCap Financial Investment Corp Q4 FY2025 earnings call

February 27, 2026 · fiscal period ended 2025-12

EPS · actual vs est

/ $0.37

Revenue · actual vs est

/ $78.9M
Ask about this call

Summary

Generated 2026-02-27

Management highlights

• Tanner Powell began with overview of fourth quarter results, share repurchase activity (purchased ~1.1 million shares at avg discount 18%, aggregate cost $12.9 million, generating ~$0.03 per share NAV accretion; Board authorized new $100 million stock repurchase plan, with ~$7.9 million remaining capacity, total $107.9 million available). • Dividend adjusted: Board declared quarterly dividend of $0.31 per share. • Ted McNulty reviewed fourth quarter investment activity: new commitments $141 million, gross fundings $156 million, sales/repayments $119 million, net fundings positive $25 million. • Portfolio details: fair value $3.17 billion, invested in 247 companies across 46 industries; direct origination 96%, Merck's 3%, liquid positions 1%; 99% first lien, 92% backed by financial sponsors in direct origination. • Software exposure details: 11.4% of portfolio, diversified, low LTV, median EBITDA $52 million. • Kenny Seifert discussed financial results: total investment income ~$78.4 million (down $4.2 million from prior quarter), net expenses $42.4 million (down $4.9 million), portfolio net loss $45.3 million, net investment income per share $0.39, gap net loss per share $0.14 (excluding one-time cost $0.10). Balance sheet: portfolio fair value $3.17 billion, total principal debt outstanding $2.00 billion, net assets $1.31 billion ($14.18 per share), net leverage 1.45 at quarter end.

View in transcript ↓

Segment performance

Net investment income per share for the quarter was $0.39. Gap net loss per share was $0.14 (including ~$0.04 one-time financing-related expenses; excluding, GAAP net loss per share was $0.10). NAV per share was $14.18 at end of December, down 3.3% from prior quarter. Fourth quarter new commitments: $141 million across 26 transactions. Net funded activity positive $25 million. Merckx paydowns: $7.5 million in December quarter, total $29.5 million by quarter end in February. At end of December, Merck's investment ~$103 million (3% of portfolio fair value), remaining investment includes 4 aircraft and servicing platform (servicing component ~29% of total value). Software exposure: 11.4% of portfolio fair value, primarily cash pay 100% first lien, diversified across 29 borrowers, low average LTV 32%, median EBITDA $52 million. Portfolio non-accrual investments: 2.6% at end of December, down from 3.1% prior quarter. Restored 2 companies to accrual, placed 3 on non-accrual. Borrower net leverage 5.29 times (unchanged from prior quarter), weighted average interest coverage ratio 2.3 times (up from 2.2 times). PIC income 4.8% of total investment income.

View in transcript ↓

Guidance

• Board authorized new $100 million stock repurchase plan, expect to utilize aggressively with 10B51 trading plan, anticipate fully utilizing current authorization by late May if current discount and trading volumes continue. • Dividend adjusted to $0.31 per share based on reassessment of long-term earning power considering rate changes and other factors. • Confidence in portfolio being well-positioned with primarily true first lien loans, limited software exposure, and visibility into expected repayments limiting impact on net leverage from stock repurchases.

View in transcript ↓

Risks

• Market risks affecting forward-looking statements, need to refer to SEC filings for risks. • Potential impact of idiosyncratic issues in certain credits, including those from vintage years, compounded by pockets of market stress. • Uncertainty regarding persistence of stock discounts and its impact on unlocking value for shareholders. • Risks associated with software exposure even though below average, including potential effects of AI disruption and credit metrics of software borrowers. • Impact of changes in base rates and spread compression on investment income and portfolio yields.

View in transcript ↓

Q&A highlights

Q: Rick Shane asked about future strategies regarding stock buybacks and unlocking value.

A: Howard responded that they'll consider everything to ensure shareholders get full value, noting they'll see how the discount persistence plays out.

Q: Kenneth Lee asked about new $100 million repurchase plan being discretionary and open trading windows.

A: Answered that it's discretionary, enter quiet periods with 10b-5-1 to maximize purchases, and expect to exhaust authorization by late May if current activity continues.

Q: Kenneth Lee followed up on dividends, asking about macro assumptions.

A: Male Speaker said $0.31 dividend was appropriate and achievable, influenced by rate changes, spreads, progress with Merck's, and capital structure initiatives to reduce cost of capital.

Q: Robert Dodd applauded buyback expansion and asked about software exposure metrics.

A: Howard responded that MidCap focused on companies with cash-long positions and embedded consistency, related to their middle market focus and focus on companies with financial covenants.

Q: Casey Alexander asked about common thread in credits from certain vintage.

A: Answered that these are longer-standing credits with idiosyncratic issues compounded by market pockets of stress and sometimes self-induced issues like aggressive acquisition strategies.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.37
Revenue$78.9M

Transcript

February 27, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.